Building a roadmap for developing combination therapies for Alzheimer's disease

Area of Science:

• Neuroscience
• Pharmacology
• Clinical Trial Design

Background:

• Combination therapy is a proven strategy for managing complex diseases.
• There is increasing interest in applying combination approaches to Alzheimer's disease treatment.
• Key stakeholders from academia, industry, and advocacy groups are involved.

Purpose of the Study:

• To address the challenges in designing clinical trials for combination therapies in Alzheimer's disease.
• To outline a roadmap for the successful implementation of such trials.

Main Methods:

• A co-hosted meeting involving the Accelerate Cure/Treatments for Alzheimer's Disease Coalition, the Critical Path Institute, and the Alzheimer's Association.
• Discussion and identification of key challenges in clinical trial design for combination treatments.

Main Results:

• Identified significant hurdles in developing and executing clinical trials for combination Alzheimer's disease therapies.
• Established a preliminary roadmap to guide future research and development.

Conclusions:

• Overcoming clinical trial design challenges is crucial for advancing combination therapy for Alzheimer's disease.
• A collaborative roadmap is essential for facilitating the development of effective combination treatments.